Similar articles

• Malignant mixed Müllerian tumor of the uterus associated with tamoxifen therapy for breast cancer.

  Magnani KK, Dubey S, Rai S. Magnani KK, et al. Indian J Pathol Microbiol. 2010 Oct-Dec;53(4):886-7. doi: 10.4103/0377-4929.72038. Indian J Pathol Microbiol. 2010. PMID: 21045469 No abstract available.
• [Malignant mixed müllerian tumor of the uterus following tamoxifen for breast cancer: case report].

  Saim M, Cote JF, Morel O, Malartic C, Akerman G, Gray F, Barranger E. Saim M, et al. Gynecol Obstet Fertil. 2008 Feb;36(2):166-168. doi: 10.1016/j.gyobfe.2007.06.020. Epub 2008 Feb 4. Gynecol Obstet Fertil. 2008. PMID: 18249575 French.
• Increased risk of malignant mullerian tumor of the uterus among women with breast cancer treated by tamoxifen.

  Bouchardy C, Verkooijen HM, Fioretta G, Sappino AP, Vlastos G. Bouchardy C, et al. J Clin Oncol. 2002 Nov 1;20(21):4403. doi: 10.1200/JCO.2002.99.174. J Clin Oncol. 2002. PMID: 12409344 No abstract available.
• Endometrial mixed Müllerian tumor with heterologous elements following tamoxifen therapy for breast cancer: a case report and literature review.

  Kaleli S, Calay Z, Altinok T, Kösebay D. Kaleli S, et al. Eur J Obstet Gynecol Reprod Biol. 2002 Mar 10;101(2):204-8. doi: 10.1016/s0301-2115(01)00529-2. Eur J Obstet Gynecol Reprod Biol. 2002. PMID: 11858901 Review.
• The optimal duration of adjuvant hormonal therapy for early-stage breast cancer.

  Winer E. Winer E. Clin Adv Hematol Oncol. 2008 Aug;6(8):573-4. Clin Adv Hematol Oncol. 2008. PMID: 18820598 Review. No abstract available.